Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
